-
GLP-1 RA use, technology, unique needs of individuals are recurring themes in the latest updates to the Standards of Care in Diabetes
Six panelists, including Elizabeth Ann Beverly, PhD, explained the latest additions and changes within selected chapters to the Standards of Care in Diabetes—2026, the gold standard in evidence-based guidelines for diagnosing and managing diabetes and prediabetes.
-
Dual GLP-1/GIP receptor agonist improves glycemic management and weight loss in adults living with type 1 diabetes and obesity
Klara Klein, MD, PhD, and other researchers shared results from a phase 2, double-blind, randomized study of acmopatide. Study participants also experienced improvements in blood pressure and insulin dosing.
-
Positive data from multiple amylin trials draw focus to novel therapeutic mechanism
Investigators, including Carel le Roux, MBChB, FRCP, FRCPath, PhD, discussed findings from monotherapy and combination trials with the pancreatic beta cell hormone. “Not only are these weight loss drugs, these are also health-gain drugs,” Dr. le Roux said.
-
Ultra-long-acting GLP-1 RA improves weight loss in individuals with and without type 2 diabetes
A Scientific Sessions panel shared new data from the VESPER trials. The long half-life of berobenatide makes investigators optimistic about its potential for monthly dosing.
-
Presenter Profile: Updates on Genitourinary Tract Infections with SGLT2 Inhibitors
Carlos E. Mendez, MD, FACP, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Monday, June 8, at 3:15 p.m. CT.
-
Investigators to bring data on glucose management with oral orforglipron
Julio Rosenstock, MD, Francesco Giorgino, MD, PhD, and other panelists will discuss results from the ACHIEVE clinical trials, including ACHIEVE-3, which compared oral semaglutide and orforglipron for use in type 2 diabetes.
-
Researchers to share VESPER phase 2 clinical trial data
Investigators, including John B. Buse, MD, PhD, will discuss new insights from the VESPER program examining berobenatide, an ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist for weight management.
-
Researchers to reveal trial results for dual agonism in type 1 diabetes
Experts, including Klara Klein, MD, PhD, will discuss the possible benefits of a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) for people living with type 1 diabetes.
-
Symposium to analyze amylin as novel therapy for diabetes and weight loss
W. Timothy Garvey, MD, and other researchers will share new insights from trials, such as REDEFINE, exploring long-acting amylin analogs as mono-agonists and in combination with agonists for other hormone receptors.
-
Experts to review the benefits and challenges of GLP-1 RAs beyond diabetes and obesity
Investigators will give an overview of new therapies coming into the market. Panelist Donna Ryan, MD, will discuss clinical trials for incretin-based therapies.